A study to look at whether longer rituximab treatment provides additional benefit in patients with non-Hodgkin lymphoma and whether this affects treatment safety (the MabCute study)
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
Cancer Non Hodgkin Lymphoma (NHL)
For the latest version of this information please go to www.forpatients.roche.com